| Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension EU/1/18/1339/001 |
Formoterol fumarate dihydrate, GLYCOPYRRONIUM |
AstraZeneca AB |
— |
| Bricanyl 500 micrograms/ml solution for injection or infusion PA1019/007/001 |
Terbutaline sulfate |
AstraZeneca AB |
Not marketed |
| Bricanyl Turbohaler 500 micrograms per metered dose, inhalation powder PA1019/007/002 |
Terbutaline sulfate |
AstraZeneca AB |
Marketed |
| Brilique 60 mg film-coated tablets EU/1/10/655/007-011 |
Ticagrelor |
AstraZeneca AB |
— |
| Brilique 90 mg film-coated tablets EU/1/10/655/001-006 |
Ticagrelor |
AstraZeneca AB |
— |
| Brilique 90 mg orodispersible tablets EU/1/10/655/012-014 |
Ticagrelor |
AstraZeneca AB |
— |
| Bydureon 2 mg powder and solvent for prolonged-release suspension for injection EU/1/11/696/001-004 |
Exenatide |
AstraZeneca AB |
— |
| Bydureon 2 mg prolonged-release suspension for injection in pre-filled pen EU/1/11/696/005-006 |
Exenatide |
AstraZeneca AB |
— |
| BYETTA 10 micrograms Solution for injection EU/1/06/362/3-4 |
Exenatide |
AstraZeneca AB |
— |
| BYETTA 5 micrograms Solution for injection EU/1/06/362/1-2 |
Exenatide |
AstraZeneca AB |
— |
| Calquence 100 mg hard capsules EU/1/20/1479/001-002 |
Acalabrutinib |
AstraZeneca AB |
— |
| Calquence film-coated tablets EU/1/20/1479/001-004 |
Acalabrutinib maleate |
AstraZeneca AB |
— |
| Daxas 250 micrograms tablets EU/1/10/636/008 |
Roflumilast |
AstraZeneca AB |
— |
| Daxas 500 micrograms film-coated tablets EU/1/10/636/001-007 |
Roflumilast |
AstraZeneca AB |
— |
| Ebymect 5 mg/1,000 mg film-coated tablets EU/1/15/1051/007-012 |
Metformin Hydrochloride, Dapagliflozin propanediol monohydrate |
AstraZeneca AB |
— |
| Ebymect 5 mg/850 mg film-coated tablets EU/1/15/1051/001-006 |
Metformin Hydrochloride, Dapagliflozin propanediol monohydrate |
AstraZeneca AB |
— |
| Edistride 10 mg film-coated tablets EU/1/15/1052/006-010 |
Dapagliflozin propanediol monohydrate |
AstraZeneca AB |
— |
| Edistride 5 mg film-coated tablets EU/1/15/1052/001-005 |
Dapagliflozin propanediol monohydrate |
AstraZeneca AB |
— |
| EVUSHELD 150 mg + 150 mg solution for injection EU/1/22/1651/001 |
Tixagevimab, Cilgavimab |
AstraZeneca AB |
— |
| Fasenra 30 mg solution for injection EU/1/17/1252/001-002 |
Benralizumab |
AstraZeneca AB |
— |
| Faslodex 250 mg Solution for injection EU/1/03/269/001-002 |
Fulvestrant |
AstraZeneca AB |
— |
| Fluenz nasal spray suspension Influenza vaccine (live, nasal) EU/1/24/1816/001-002 |
REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) B/<OFFICIAL STRAIN> LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML, REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) A/<OFFICIAL STRAIN> (H3N2) LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML, REASSORTANT INFLUENZA VIRUS (LIVE ATTENUATED) A/<OFFICIAL STRAIN> (H1N1) LIKE STRAIN (<ACTUAL STRAIN>) 10^7.0±0.5 FLUORESCENT FOCUS UNITS PER 0.2 ML |
AstraZeneca AB |
— |
| Forxiga 10 mg film-coated tablets EU/1/12/795/006-010 |
Dapagliflozin propanediol monohydrate equivalent to 10mg dapagliflozin |
AstraZeneca AB |
— |
| Forxiga 5 mg film-coated tablets EU/1/12/795/001-005 |
Dapagliflozin propanediol monohydrate equivalent to 5mg dapagliflozin |
AstraZeneca AB |
— |
| IMFINZI 50 mg/ml concentrate for solution for infusion. EU/1/18/1322/001-002 |
Durvalumab |
AstraZeneca AB |
— |
| IMJUDO 20 mg/ml concentrate for solution for infusion EU/1/22/1713/001-002 |
Tremelimumab |
AstraZeneca AB |
— |
| Iressa 250 mg film-coated tablets EU/1/09/526/001-002 |
Gefitinib |
AstraZeneca AB |
— |
| KAVIGALE 300 mg solution for injection/infusion EU/1/24/1900/001 |
Sipavibart |
AstraZeneca AB |
— |
| Komboglyze 2.5 mg/1000 mg film-coated tablets EU/1/11/731/007-012 |
Metformin Hydrochloride, Saxagliptin |
AstraZeneca AB |
— |
| Komboglyze 2.5 mg/850 mg film-coated tablets EU/1/11/731/001-006 |
Saxagliptin, Metformin Hydrochloride |
AstraZeneca AB |
— |
| Koselugo 10 mg hard capsules EU/1/21/1552/001 |
Selumetinib Sulfate |
AstraZeneca AB |
— |
| Koselugo 25 mg hard capsules EU/1/21/1552/002 |
Selumetinib Sulfate |
AstraZeneca AB |
— |
| Lokelma 10 g powder for oral suspension EU/1/17/1173/003-004 |
Sodium zirconium cyclosilicate |
AstraZeneca AB |
— |
| Lokelma 5 g powder for oral suspension EU/1/17/1173/001-002 |
Sodium zirconium cyclosilicate |
AstraZeneca AB |
— |
| Lynparza 100 mg Film-coated tablet EU/1/14/959/002-003 |
Olaparib |
AstraZeneca AB |
— |
| Lynparza 150 mg Film-coated tablet EU/1/14/959/004-005 |
Olaparib |
AstraZeneca AB |
— |
| Ondexxya Powder for solution for infusion EU/1/18/1345/001 |
Andexanet alfa |
AstraZeneca AB |
— |
| Onglyza 2.5 mg film-coated tablets EU/1/09/545/011-015 |
Saxaglitpin |
AstraZeneca AB |
— |
| Onglyza 5 mg film-coated tablets EU/1/09/545/1-10 |
Saxagliptin |
AstraZeneca AB |
— |
| Oxis Turbohaler 12, inhalation powder PA1019/015/002 |
Formoterol fumatrate dihydrate |
AstraZeneca AB |
Not marketed |
| Oxis Turbohaler 6, inhalation powder PA1019/015/001 |
Formoterol fumatrate dihydrate |
AstraZeneca AB |
Not marketed |
| Pandemic influenza vaccine H5N1 AstraZeneca nasal spray, suspension. Pandemic influenza vaccine (H5N1) (live attenuated, nasal). EU/1/16/1089/001 |
Strain. a/vietnam/1203/2004 (h5n1) strain (live attenuated) |
AstraZeneca AB |
— |
| Pulmicort Respules 0.5 mg/2 ml Nebuliser Suspension PA1019/017/001 |
Budesonide |
AstraZeneca AB |
Marketed |
| Pulmicort Respules 1 mg /2 ml Nebuliser Suspension PA1019/017/002 |
Budesonide |
AstraZeneca AB |
Marketed |
| Pulmicort Turbohaler 100 micrograms Inhalation Powder PA1019/017/003 |
Budesonide |
AstraZeneca AB |
Not marketed |
| Pulmicort Turbohaler 200 micrograms Inhalation Powder PA1019/017/004 |
Budesonide |
AstraZeneca AB |
Marketed |
| Pulmicort Turbohaler 400 micrograms Inhalation Powder PA1019/017/005 |
Budesonide |
AstraZeneca AB |
Not marketed |
| Qtern 5 mg/10 mg film-coated tablets EU/1/16/1108/001-004 |
Dapagliflozin, Saxagliptin |
AstraZeneca AB |
— |
| Riltrava Aerosphere 5/7.2/160 micrograms pressurised inhalation, suspension EU/1/21/1604/001-002 |
Formoterol fumarate dihydrate, Glycopyrronium bromide, Budesonide |
AstraZeneca AB |
— |
| Saphnelo 300 mg Concentrate for solution for infusion EU/1/21/1623/001 |
Anifrolumab |
AstraZeneca AB |
— |